Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling-Reference-Cited by-同舟云学术

Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling

Published:2023-02-06 Issue: Volume: Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Chirehwa M. T.¹^ORCID,Resendiz-Galvan J. E.¹^ORCID,Court R.¹,De Kock M.²,Wiesner L.¹^ORCID,de Vries N.³,Harding J.⁴,Gumbo T.⁵,Warren R.²,Maartens G.¹^ORCID,Denti P.¹^ORCID,McIlleron H.¹⁶

Affiliation:

1. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa

2. DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, SAMRC Centre for Tuberculosis Research, Stellenbosch University, Cape Town, South Africa

3. Brooklyn Chest Hospital, Cape Town, South Africa

4. DP Marais Hospital, Cape Town, South Africa

5. Quantitative Preclinical and Clinical Sciences Department, Praedicare Inc., Dallas, Texas, USA

6. Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Abstract

Moxifloxacin is included in some treatment regimens for drug-sensitive tuberculosis (TB) and multidrug-resistant TB (MDR-TB). Aiming to optimize dosing, we described moxifloxacin pharmacokinetic and MIC distribution in participants with MDR-TB.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01426-22

Reference50 articles.

1. World Health Organization. 2022. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland.

2. World Health Organization. 2020. WHO consolidated guidelines on tuberculosis module 4: treatment - drug-resistant tuberculosis treatment. https://www.who.int/publications/i/item/9789240007048. Retrieved 20 April 2022.

3. Moxifloxacin Hydrochloride

4. Pharmacology of Moxifloxacin — Absorption, Distribution, Metabolism and Excretion

5. Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB